Vertex Pharmaceuticals | VRTX - Current Liabilities



Vertex Pharmaceuticals reported $4.14B in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
AbbVie USD 36.4B 2.35B Mar/2025
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
Agios Pharmaceuticals USD 70.41M 18.04M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 225.22M Jun/2025
Amgen USD 20.48B 2.53B Jun/2025
Arrowhead Research USD 194.53M 26.01M Jun/2025
Biogen USD 3.18B 2.11B Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Incyte USD 1.28B 608.18M Jun/2025
Insmed USD 311.68M 72.45M Jun/2025
Ionis Pharmaceuticals USD 897.24M 646.94M Jun/2025
J&J USD 56.9B 6.58B Mar/2025
Merck USD 26.04B 863M Jun/2025
Moderna USD 1.57B 32M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
Novartis USD 31.71B 95M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
PTC Therapeutics USD 627.81M 32.42M Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Roche Holding CHF 27.02B 424M Dec/2024
Sanofi 29.06B 3.16B Jun/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
United Therapeutics USD 527.1M 194.4M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025